Established in 1994, Current Oncology is a peer-reviewed, Canadian based and Internationally respected journal. Published bi-monthly plus special supplemental issues, Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is published by Multimed Inc.

Current Oncology is indexed/covered in MEDLINE, PubMed, Embase, Scopus, Crossref, Index Copernicus, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC), the U.S. National Library of Medicine's digital archive of biomedical and life sciences journal literature. It is also available in the databases of 100 libraries worldwide, and is a participant of the HINARI program.

The information provided on the Current Oncology website is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.


CANADIAN PERSPECTIVES: Management of Chronic Lymphocytic Leukemia in Canada During the Coronavirus Pandemic


In a paper on the management of chronic lymphocytic leukemia (CLL) during the COVID-19 pandemic, Dr. Laurie Sehn (BC Cancer Centre for Lymphoid Cancer, Vancouver), Dr. Philip Kuruvilla (William Osler Health Center, Brampton), and Dr. Julie Stakiw (Saskatoon Cancer Centre, Saskatoon) discuss the current American Society for Hematology (ASH) recommendations and their applicability as guidelines for the treatment of CLL during the COVID-19 pandemic in Canada. The paper is published in the June 2020 issue of Current Oncology: Volume 27, Number 3.

Read more about CANADIAN PERSPECTIVES: Management of Chronic Lymphocytic Leukemia in Canada During the Coronavirus Pandemic

Soft-tissue Sarcoma Supplement Now Online

Soft-tissue sarcomas have been, until recently, a neglected topic of investigation and publication. This is explained, in comparison with epithelial cancers, by a slower understanding of their pathogenesis and a lack of effective systemic therapies. The past few years, however, have seen changes in their classification, as well as improvements in their treatment, from surgery and radiotherapy to systemic therapy. Our Guest Editor, Dr. Thierry Alcindor (Associate Professor of Oncology & Medicine at McGill University) revisits soft-tissue sarcomas in this special journal issue. Read more about Soft-tissue Sarcoma Supplement Now Online

Current Issue

Published: 2020-06-30


Original Article(s)

Surgical Oncology

Cancer Control and Prevention

Short Communication(s)

Cancer Narratives: Words Beyond Disease

Practice Guideline(s)

Case Report(s)

Review Article(s)



Letter(s) to the Editor